We hope you are enjoying 340B Report’s new website and email platform that we launched yesterday. If you or a colleague did not receive the issue in your in-box, please make sure to mark us as a safe sender and add
Blog Posts
The National Association of Community Health Centers (NACHC) last night on its members’ behalf asked a new federal 340B program administrative dispute resolution (ADR) panel to order drug manufacturers Eli Lilly and Co., Sanofi, and AstraZeneca to lift all “qualifications,
…
340B program stakeholders are still digesting drug manufacturers AstraZeneca, Eli Lilly and Co., and Sanofi’s Jan. 12 lawsuits to block federal sanctions over their decisions to stop or impose conditions on 340B discounts on drugs dispensed by contract pharmacies.
Nevada’s AIDS Drug Assistance Program (ADAP) on Tuesday postponed “through April 1, 2021, if not longer,” a 340B program policy change strongly opposed by the state’s Ryan White CARES Act grantees. The state health department’s Division of Public and Behavioral
…
As 2020 comes to a close, we recognize it has been a year like no other! Dominated by challenges and uncertainty with the pandemic and the economy, and the political landscape overshadowing everything. As always, and particularly in the face
…
In a major escalation of the fight over 340B contract pharmacy, drug manufacturer AstraZeneca late yesterday asked a federal court to declare that it “is not required to offer 340B discounts to contract pharmacies.”
Please Login
We are excited to introduce you to 340B Report’s new website and email platform. It’s the culmination of many months of hard work, and we are very proud. We want to thank 340B Report’s Reshma Eggleston, Diane Slafsky and Inci
…
The U.S. Health Resources and Services Administration (HRSA) Tuesday afternoon posted a new webpage describing the steps health care providers and drug manufacturers must follow to invoke the 340B program’s new administrative dispute resolution (ADR) process. It simultaneously posted 11
…
Drug manufacturer Bausch Health blindsided 340B covered entities on New Year’s Eve, announcing that starting the very next day, Jan. 1, more than 200 of its branded products and future branded products would no longer be available through distributor AmerisourceBergen
…
The incoming Democratic chairs of two key U.S. Senate committees want the federal agency in charge of the 340B program “to take immediate action to clarify that implementation of a rebate model by [drug] manufacturers would violate a material condition
…